Benign Chronic Diarrhea of Infancy

1981 ◽  
Vol 3 (5) ◽  
pp. 153-158
Author(s):  
W. Allan Walker
Keyword(s):  
Irritable Bowel Syndrome ◽  
Chronic Diarrhea ◽  
Spontaneous Resolution ◽  
Gastrointestinal Problems ◽  
High Incidence ◽  
Bowel Movements ◽  
Separate Clinical Entity ◽  
Irritable Bowel ◽  
Classic Paper ◽  
Referral Practice

Chronic nonspecific diarrhea of infancy (CNSD) or irritable bowel syndrome represents one of the most common gastrointestinal problems confronted by practicing pediatricias. In the subspecialty setting of the pediatric gastroenterologist, this entity comprised almost 35% of the outpatient referral practice. CNSD, originally thought to be part of the celiac syndrome, was described as a separate clinical entity by Cohlan in 1956.1 Since that time in the classic paper on this subject, Davidson and Wasserman2 have described consistent diagnostic criteria further characterizing CNSD as a recognizable syndrome. The onset of symptoms occurs classically between 6 and 30 months of age with the development of three to six loose stools with mucous per day, with no associated malabsorption or growth and development abnormalities (to be discussed in detail below). Whereas spontaneous resolution of CNSD is anticipated by 39 months of age, longitudinal observations indicate that these patients have a high incidence of functional bowel complaints during adolescence and beyond suggesting a continuum with "irritable bowel syndrome" of adulthood.3 From the standpoint of the child, this "complaint" all too frequently becomes the "problem" when the frequency and/or consistency of the bowel movements impair training or become intolerable to the parents.

scholarly journals EFFICACY AND SAFETY OF INTESTINAL SECRETAGOGUES FOR CHRONIC CONSTIPATION: A SYSTEMATIC REVIEW AND META-ANALYSIS

2018 ◽  
Vol 55 (suppl 1) ◽  
pp. 2-12 ◽  
Author(s):  
Juan Sebastian LASA ◽  
María Josefina ALTAMIRANO ◽  
Luis Florez BRACHO ◽  
Silvina PAZ ◽  
Ignacio ZUBIAURRE
Keyword(s):  
Irritable Bowel Syndrome ◽  
Chronic Constipation ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Spontaneous Bowel Movement ◽  
Intention To Treat ◽  
Mesh Terms ◽  
Bowel Movements ◽  
Irritable Bowel ◽  
Therapeutic Alternatives

ABSTRACT BACKGROUND: Intestinal secretagogues have been tested for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome. The class-effect of these type of drugs has not been studied. OBJECTIVE: To determine the efficacy and safety of intestinal secretagogues for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome. METHODS: A computer-based search of papers from 1966 to September 2017 was performed. Search strategy consisted of the following MESH terms: intestinal secretagogues OR linaclotide OR lubiprostone OR plecanatide OR tenapanor OR chloride channel AND chronic constipation OR irritable bowel syndrome. Data were extracted as intention-to-treat analyses. A random-effects model was used to give a more conservative estimate of the effect of individual therapies, allowing for any heterogeneity among studies. Outcome measures were described as Relative Risk of achieving an improvement in the symptom under consideration. RESULTS: Database Search yielded 520 bibliographic citations: 16 trials were included for analysis, which enrolled 7658 patients. Twelve trials assessed the efficacy of intestinal secretagogues for chronic constipation. These were better than placebo at achieving an increase in the number of complete spontaneous bowel movements per week [RR 1.87 (1.24-2.83)], at achieving three or more spontaneous bowel movements per week [RR 1.56 (1.31-1.85)] and at inducing spontaneous bowel movement after medication intake [RR 1.49 (1.07-2.06)]. Similar results were observed when assessing the efficacy of intestinal secretagogues on constipation-predominant irritable bowel syndrome based on the results of six trials. CONCLUSION: Intestinal secretagogues are useful and safe therapeutic alternatives for the treatment of constipation-related syndromes.

Irritable bowel syndrome – a common problem, individual approach

2021 ◽  
Vol 14 (4) ◽  
pp. 369-374
Author(s):  
Barbara Skrzydło-Radomańska ◽  
Bartosz J. Sapilak
Keyword(s):  
Irritable Bowel Syndrome ◽  
Clinical Symptoms ◽  
Recurrent Abdominal Pain ◽  
Frequency Change ◽  
High Fiber ◽  
Fiber Diet ◽  
Bowel Movements ◽  
Irritable Bowel ◽  
Effective Drugs

Irritable bowel syndrome is a recurrent abdominal pain that occurs at least once a week for 3 months, with symptoms at least 6 months associated with at least two features: bowel movements, change in bowel frequency, change in the appearance of stools. According to the Rome IV Diagnostic Criteria, the disease is diagnosed on the basis of clinical symptoms. This does not apply to people over 50 years of age (and in the case of first-degree relatives of patients with colorectal cancer after 45 years of age) and patients with alarm symptoms. Due to the lack of a single etiological factor, the treatment of irritable bowel syndrome consists in reducing symptoms and improving the patient’s quality of life. Non-pharmacological treatment includes a high-fiber diet and modification of the microbiota. The most effective drugs are antispasmodics directly affecting the smooth muscle, inhibiting the influx of calcium, i.e. drotaverine, mebeverine and alverine. There has been proven effectiveness of antidepressants. This confirms that functional disorders of the gastrointestinal tract are a manifestation of the dysfunction of the brain–gut–microbiota axis.

scholarly journals Understanding the Psychosocial and Parenting Needs of Mothers with Irritable Bowel Syndrome with Young Children

Children ◽  
2020 ◽  
Vol 7 (8) ◽  
pp. 93
Author(s):  
Lexa K. Murphy ◽  
Tanera R. van Diggelen ◽  
Rona L. Levy ◽  
Tonya M. Palermo
Keyword(s):  
Irritable Bowel Syndrome ◽  
Intervention Program ◽  
Preventive Intervention ◽  
Qualitative Interviews ◽  
Signs And Symptoms ◽  
School Age Children ◽  
Healthy Children ◽  
Childbearing Age ◽  
Gastrointestinal Problems ◽  
Irritable Bowel

Women of childbearing age experience the highest prevalence of irritable bowel syndrome (IBS), yet little is known about their psychosocial and parenting needs, which may influence their children’s experience of future gastrointestinal or pain-related conditions. The aims of this study were to conduct qualitative interviews to understand the psychosocial and parenting needs of mothers with IBS who have young school-age children, and to assess mothers’ potential interest in and acceptability of a preventive parenting intervention program. Ten mothers with IBS who have young (age 5–10), healthy children were interviewed. Interviews were coded with thematic analysis and three themes were identified: (1) Guilt about how IBS impacts children, (2) Worry that children will develop IBS, and (3) Already on high alert for children’s health. All mothers expressed interest in an Internet-based preventive intervention and identified tools and strategies they would want included. Results demonstrate that mothers experience guilt about how IBS has impacted their children in their daily lives, concern that they need to pay attention to children’s early signs and symptoms that could indicate gastrointestinal problems, and worry about children developing IBS in the future—suggesting that a preventive intervention may address important concerns for this population.

scholarly journals Inflammatory Bowel Diseases and Irritable Bowel Syndrome: Overlap of Two Nosological Forms or Two Variants of the Same Disease?

2019 ◽  
Vol 29 (5) ◽  
pp. 43-48
Author(s):  
A. A. Sheptulin ◽  
K. E. Vinogradskaya
Keyword(s):  
Inflammatory Bowel Disease ◽  
Irritable Bowel Syndrome ◽  
Inflammatory Bowel Diseases ◽  
Bowel Disease ◽  
High Incidence ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Irritable Bowel ◽  
The Relationship

Aim. To review available literature data on the relationship between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).Key findings. Current publications on IBD and IBS present different viewpoints on their relationship. Thus, researchers have noted a high incidence of IBD against the background of IBS, frequent persistence of IBS-like symptoms after achieving IBD remission, as well as the possibility of overlapping the diseases. According to literature data, IBD and IBS should be treated as different forms of the same disease. An opinion is expressed that IBS-like complaints in patients with IBD remission should be considered as a separate disease referred to as “irritated inflammatory intestinal syndrome”. Treatment of IBS-like symptoms in patients with IBD remission has thus far not been developed.Conclusion. The problem of the relationship between IBD and IBS is currently controversial, thus requiring further clarification.

Efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in a real‑world setting – results from a German noninterventional study

2018 ◽  
Vol 56 (07) ◽  
pp. 738-744 ◽  
Author(s):  
Viola Andresen ◽  
Stephan Miehlke ◽  
Elmar Beck ◽  
Gwen Wiseman ◽  
Peter Layer
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Clinical Practice ◽  
Real World ◽  
Common Adverse Event ◽  
Routine Clinical Practice ◽  
Guanylate Cyclase C ◽  
Bowel Movements ◽  
Irritable Bowel ◽  
Noninterventional Study

Abstract Background Linaclotide is a minimally absorbed peptide guanylate cyclase-C agonist approved for the treatment of irritable bowel syndrome with constipation (IBS-C). This study assessed the efficacy and tolerability of linaclotide in IBS-C in routine clinical practice in Germany. Methods This was a 52-week, noninterventional study of linaclotide in patients aged ≥ 18 years with moderate to severe IBS-C. Severity of abdominal pain and bloating and frequency of bowel movements were assessed over 5 study visits. Treatment-related adverse events were recorded. Results The study enrolled 375 patients; the mean observation duration was 4.4 months. Linaclotide marketing was halted during the study period for economic reasons, accounting for low patient numbers and short observation duration. Linaclotide significantly reduced mean (standard deviation [SD]) scores between treatment start (visit 1) and study end (visit 5) for abdominal pain intensity (visit 1: 4.87 [2.63] vs. visit 5: 2.40 [2.20], p < 0.0001), mean [SD] bloating intensity (visit 1: 5.30 [2.70] vs. visit 5: 2.86 [2.34], p < 0.0001), and increased mean [SD] bowel movement frequency (visit 1: 2.71 [1.80] vs. 4.38 [1.86], p < 0.0001). Diarrhea, occurring in 5.1 % of patients, was the most common adverse event. Conclusion Linaclotide is effective in improving the major symptoms of IBS-C and demonstrates a favorable safety profile in the real-world environment of routine clinical practice. DRKS (www.drks.de/): DRKS00005088.

The Irritable Bowel Syndrome

2019 ◽  
pp. 435-458
Author(s):  
Nuha Alammar ◽  
Gerard Mullin
Keyword(s):  
Primary Care ◽  
Irritable Bowel Syndrome ◽  
Primary Care Physicians ◽  
Gastrointestinal Disorder ◽  
Therapeutic Strategies ◽  
Organic Disease ◽  
Bowel Movements ◽  
Disease Subtypes ◽  
Irritable Bowel ◽  
Rome Iv

The irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by chronic nonspecific abdominal pain with altered bowel movements in the absence of known organic disease. IBS is diagnosed by the Rome IV criteria for functional GI disorders. Although research has shown several factors that might be contributing to IBS pathophysiology, there is no specific cause for this disorder identified yet. There are four disease subtypes found in equal proportions: diarrhea, constipation, mixed, and undefined (IBS-U). IBS is a prevalent disorder that primary care physicians evaluate in the clinic. In this chapter, the authors review the epidemiology and updated research regarding its pathophysiology, diagnostics, and integrative therapeutic strategies.

Sign in / Sign up

Export Citation Format

Share Document